Zentalis Strengthens Leadership With Key Appointments

Zentalis® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative small molecule therapies for cancer. The firm has announced two key leadership appointments. Wendy Chang has been named Chief People Officer, and Haibo Wang will serve as Chief Business Officer.

Julie Eastland, Chief Executive Officer, said, "Zentalis is sharply focused on our goal of bringing azenosertib to patients with gynaecological malignancies. To support this goal, we continue to tune our leadership team. Today, we announced the appointment of two talented leaders with a strong track record of successfully supporting organizations through transitional periods. I look forward to working with Wendy, Haibo, and the rest of the leadership team as we advance the development of azenosertib.”

Wendy Chang is now Chief People Officer at Zentalis, she will be bringing over 20 years of biopharma HR experience. Previously, she held leadership roles at Harpoon Therapeutics, IDbyDNA, and Gilead Sciences. Wendy earned her B.S. from UC Riverside and completed a talent management program at Wharton.

Whereas Mr Haibo Wang as Chief Business Officer at Zentalis, has over 15 years of experience in biopharma business development, finance, and M&A. He led Harpoon Therapeutics’ acquisition by Merck and held key roles at Hummingbird Bioscience and Amgen, contributing to significant acquisitions and partnerships. Haibo holds degrees from Johns Hopkins, Duke, and Tsinghua University.